Fludarabine, Rituximab, and Alemtuzumab for B-Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma, Small Lymphocytic, Lymphocytic Leukemia, Chronic

In brief

This purpose of this study is to assess the toxicity and the rate of complete and overall response using fludarabine, rituximab, and alemtuzumab to treat patients with B-chronic lymphocytic leukemia or small lymphocytic leukemia who have received previous treatment.

Key facts

Study ID

NCT00143065

Run by

Ohio State University Comprehensive Cancer Center

People needed

8

Starts

2005-08-01

Expected to finish

2009-07-01

Last updated by the study team

2017-02-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have B-CLL/SLL
• active disease
• >=1 prior systemic therapy
• ECOG PS 0-2.

You may not qualify if…

• Pregnant or nursing women

Where it is running

• Ohio State University — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.